Principles And Practice Of Pharmaceutical Medicine


Published on

Published in: Education
  • thank for good question
    Are you sure you want to  Yes  No
    Your message goes here
  • Treating arrhythmia the standard way (drugs + operations) can be pretty expensive. Of course, in some cases this is the only cure, but in other cases arrhythmia can be cured and can ONLY be cured by following a certain diet. But you have go through some tests first to see if your arrhythmia is caused by a physical flaw in your heart or from other factors (stress, bad nutrition, etc.). How do I know it works? I’m a living example! None of three different pills doctors prescribed me had any effect, but the change of diet did. Read my whole story (along with complete medical documentation) here:
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Principles And Practice Of Pharmaceutical Medicine

  1. 1. Principles and Practice of Pharmaceutical Medicine Second Edition
  2. 2. Principles and Practice of Pharmaceutical Medicine Second Edition Edited by Lionel D. Edwards Novartis and Pharma Pro Plus Inc. New Jersey, USA Andrew J. Fletcher Temple University School of Pharmacy, Philadelphia, USA Anthony W. Fox EBD Group Inc., California, USA and Munich, Germany and Skaggs SPPS, University of California, San Diego Peter D. Stonier Consultant in Pharmaceutical Medicine, Richmond, Surrey, UK
  3. 3. Copyright ß 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (þ44) 1243 779777 Email (for orders and customer service enquiries): Visit our Home Page on or All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to, or faxed to (þ44) 1243 770620. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. Other Wiley Editorial Offices John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, Australia John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809 John Wiley & Sons Canada Ltd, 6045 Freemont Blvd, Mississauga, Ontario, L5R 4J3, Cananda Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Anniversary Logo Design: Richard J. Pacifico Library of Congress Cataloging-in-Publication Data Principles and practice of pharmaceutical medicine/edited by Lionel D. Edwards ... [et al.]. – 2nd ed. p.; cm. Includes bibliographical references and index. ISBN 978-0-470-09313-9 (cloth: alk. paper) 1. Drug development. 2. Drugs–Research. 3. Pharmacology. I. Edwards, Lionel D. [DNLM: 1. Drug Evaluation. 2. Drug Industry–organization & administration. QV 736 P9567 2007] RM301.25.P75 2007 615’.19–dc22 2007011029 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library ISBN 978-0-470-09313-9 Typeset in 10.5/12.5 pt Times by Thomson Digital, India Printed and bound in Great Britain by Antony Rowe Ltd., Chippenham, Wilts This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.
  4. 4. Contents Preface to the First Edition ix Preface to the Second Edition xi About the Editors xiii Contributors xv SECTION I: OVERVIEW OF PHARMACEUTICAL MEDICINE 1 1 The Practice and Practitioners of Pharmaceutical Medicine 3 Anthony W. Fox 2 Pharmaceutical Medicine as a Medical Specialty 7 Michael D. Young and Peter D. Stonier 3 Clinical Research Education and Training for Biopharmaceutical Staff 25 Peter Marks SECTION II: DRUG DISCOVERY AND DEVELOPMENT 41 Introduction 41 4 Drug Discovery: Design and Serendipity 43 Ronald R. Cobb and Leslie J. Molony 5 Pharmaceutics 51 Anthony W. Fox 6 Nonclinical Toxicology 63 Frederick Reno 7 Informed Consent 75 Anthony W. Fox 8 Phase I: The First Opportunity for Extrapolation from Animal Data to Human Exposure 79 Stephen H. Curry, Dennis McCarthy, Helen H. DeCory, Matthew Marler and Johan Gabrielsson 9 Phase II and Phase III Clinical Studies 101 Anthony W. Fox 10 Phase IV Drug Development: Post-Marketing Studies 119 Lisa R. Johnson-Pratt
  5. 5. vi CONTENTS 11 Site Management 127 Barry Miskin 12 Good Clinical Practices 139 Wendy Bohaychuk and Graham Ball 13 Quality Assurance, Quality Control and Audit 159 Rita Hattemer-Apostel 14 The Unique Role of Over-the-Counter Medicine 179 Paul Starkey SECTION III: SPECIAL POPULATIONS AND REQUIRED SPECIAL STUDIES 191 Introduction 191 15 Drug Research in Older Patients 193 Lionel D. Edwards 16 Drug Development Research in Women 203 Lionel D. Edwards 17 Clinical Research in Children 223 Lionel D. Edwards 18 Racial and Ethnic Issues in Drug Registration 231 ´ Lionel D. Edwards, J.M. Husson, E. Labbe, C. Naito, M. Papaluca Amati, S. Walker, R. Williams and H. Yasurhara 19 Hepatic and Renal Failure 249 Anthony W. Fox 20 Drug Interactions 255 Anthony W. Fox and Anne-Ruth van Troostenburg de Bruyn 21 Orphan Drugs 265 Bert Spilker SECTION IV: APPLIED ASPECTS OF DRUG DEVELOPMENT 277 Introduction 277 22 Biotechnology Products and Development 279 David A. Shapiro and Anthony W. Fox 23 Pharmacoeconomics: Economic and Humanistic Outcomes 291 Raymond J. Townsend, Jane T. Osterhaus and J. Gregory Boyer 24 Pharmacoepidemiology and the Pharmaceutical Physician 303 Hugh H. Tilson 25 Statistical Principles and Application in Biopharmaceutical Research 313 Dan Anbar 26 Data Management 345 T.Y. Lee and Michael Minor
  6. 6. CONTENTS vii 27 Patient Compliance: Pharmionics, a New Discipline 355 ´ Jean-Michel Metry 28 Monitoring Drug Concentrations in Clinical Practice 375 Anthony W. Fox 29 Generics 381 J.D. Gabriel Lopez and J.D. Thomas Hoxie 30 Complementary Medicines 387 Anthony W. Fox SECTION V: DRUG REGULATION 393 Introduction 393 31 United States Regulations 395 William Kennedy 32 Special US Regulatory Procedures: Emergency and Compassionate INDs and Accelerated Product Approvals 407 Anthony W. Fox 33 The Development of Human Medicines Control in Europe from Classical Times to the Year 2000 415 John P. Griffin 34 Medicines Regulation in the European Union 443 Anne-Ruth van Troostenburg de Bruyn and Giuliana Tabusso 35 Japanese Regulations 487 ´ Etienne Labbe 36 Drug Registration and Pricing in the Middle East 509 Edda Freidank-Mueschenbornfs SECTION VI: MEDICAL SERVICES 517 Introduction 517 37 Medical Affairs 519 Gregory P. Geba 38 Drug Labeling 529 Anthony W. Fox 39 Drug Surveillance 535 Howard J. Dreskin and Win M. Castle 40 Data Mining 545 Mirza I. Rahman and Omar H. Dabbous 41 Risk Management in Product Approval and Marketing 557 Anthony W. Fox
  7. 7. viii CONTENTS 42 Publishing Clinical Studies 565 Anthony W. Fox 43 Organizing and Planning Local, Regional, National and International Meetings and Conferences 575 Zofia Dziewanowska and Linda Packard 44 Drug Withdrawals from the Market – Causes and Consequences 579 Ronald D. Mann SECTION VII: LEGAL AND ETHICAL ASPECTS OF PHARMACEUTICAL MEDICINE 585 Introduction 585 45 Introduction to Bioethics for Pharmaceutical Professionals 587 Andrew J. Fletcher 46 Pharmaceutical Medicine and the Law 595 Sarah Croft and Timothy Pratt 47 Pharmaceutical Product Liability 605 Han W. Choi and Howard B. Yeon 48 Patents 619 Gabriel Lopez 49 Fraud and Misconduct in Clinical Research 631 Jane Barrett SECTION VIII: BUSINESS ASPECTS 643 Introduction 643 50 The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment 645 R. Drucker and R. Graham Hughes 51 Advertising and Marketing 653 Jonathan Belsey 52 Middle East, India, China and the Far East: Pharmaceutical Medicine in the East 665 Gamal Hammad 53 Financial Aspects of Clinical Trials 689 R.G. Hughes and N. Turner 54 Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors 701 John R. Vogel 55 The Impact of Managed Care on the US Pharmaceutical Industry 725 Robert J. Chaponis, Christine Hanson-Divers, and Marilyn J. Wells Appendix: Useful Internet Links 745 Index 749
  8. 8. Preface to the First Edition Pharmaceutical medicine is a relatively new, but rapidly growing, academic discipline. As these trends continue into the 21st century, pharmaceutical physicians are increasingly regarding consultancy work and contract research organization (CRO) affiliation as good career opportunities, and now recognize the need for continuing education and training in this broad spectrum discipline. As editors, we would like to thank our contributors for their expertise, their dedication, and their vision. We would like to thank and acknowledge the work and counsel of our colleague Robert Bell, MD, MRPharmS, who helped us greatly during the early part of this project. We would also like to thank and acknowledge the enormous help, encouragement, and patience of the team at John Wiley & Sons, Inc., UK, with whom we have worked closely over these past few years, among whom we have particularly stressed (!) Michael Davis, Deborah Reece, Hannah Bradley, Lewis Derrick, and Hilary Rowe. Lastly, we would like to thank our families, and friends, who have withstood the frequent telephone calls, e-mails, and meetings, often late into the night. Indeed, to all who made this project possible, both authors and non-authors, we thank you. We are certain that this specialty, and our patients, even though we may help them vicariously, will benefit because of your contributions. Andrew Fletcher Lionel Edwards Tony Fox Peter Stonier
  9. 9. Preface to the Second Edition Since the first edition of this book, pharmaceutical medicine has only become more diverse and has also become widely accepted as a recognized medical specialty, for example, with its first graduates of specialist training in the United Kingdom, to add to those of Switzerland, and Mexico. This has been accompanied by pharmaceutical medicine’s rapid progress toward specialty recognition within the European Community, and many changes in the pharmaceutical environment. So, we have taken this book further with this second edition. There are new chapters on European regulations, risk management, the Middle East, Asia and other topical subjects in pharmaceutical medicine. Those chapters that did appear in the first edition have all been brought up to date. But this book is for all those working in pharmaceutical medicine, regardless of their degrees, titles or affiliations. Although it comprehensively covers the internationally harmonized syllabus for the Diplomas in Pharmaceutical Medicine that are awarded in Belgium, Switzerland and the United Kingdom, this book will also usefully serve those teaching other types of certificates and (usually Master’s) degrees in this field, as well as being a vade mecum for those who are not undertaking academic courses. We would again like to thank the team at John Wiley and Sons, Inc., Chichester (UK). Hannah Bradley got this second edition started, but then went off on a tour around the world; the editors strenuously deny that they are the reason why. Lucy Sayer and Juliet Booker have since piloted the ship to the dock-side, successfully cajoling us into getting this edition done before its second decade. Not least, we would like to thank you, the reader, for your continued support and suggestions. So here is our second edition, it is more than a simple update, and it is even less US-centric than before. Lionel Edwards Andrew Fletcher Tony Fox Peter Stonier
  10. 10. About the Editors LIONEL D. EDWARDS, MB, BS, LRCP, MRCS, DipRCOG, FFPM, is Senior Director of Medical Affairs for Novartis USA, and President of Pharma Pro Plus Inc., a drug development consulting company. Dr. Edwards has been involved in all aspects of clinical trials for over 33 years on many different research drug and devices in 10 therapeutic areas. Previously, he was Vice President of Clinical Research at Bio- Technology Pharmaceutical Corporation, a small biotechnology firm operating both in the United States and internationally. Prior to this, he worked at Noven Inc., a small Skin Patch Technology firm with large internationally licensed partners – CIBA and Rhone Poulenc Rorer. He was Assistant Vice President, International Clinical Research at Hoffman-La Roche, Senior Director of Schering-Plough International Research, and Director of US Domestic Gastrointestinal, Hormonal, and OTC Research Departments. Dr. Edwards chaired the PMA Special Population Committee, and also sat on the Institute of Medicine Committee for Research in Women, sponsored by the US National Instutes of Health. He also served on the efficacy subcommittee Topic 5 (Acceptability of Foreign Clinical Data) for the International Committee on Harmonization (ICH). Dr. Edwards is a Fellow of the Faculty of Pharmaceutical Medicine and an Adjunct Professor at Temple University Graduate School of Pharmacology. He has taught for the Pharmaceutical Education & Research Institute for over 12 years and was on the teaching faculty of the National Association of Physicians. He is a founder member of the American Academy of Pharmaceutical Physicians. Dr. Edwards has homes in New Jersey and Florida. ANDREW J. FLETCHER, MB, BChir, (Cantab), MS (Columbia), DipPharmMedRCP, FFPM was formerly the Senior Assistant Editor of The Merck Manual, and is Adjunct Professor of Pharmaceutical Health Care at Temple University School of Pharmacy. He graduated from Cambridge University and St. Bartholomew’s Hospital, London, briefly trained in Neurosurgery, joined CIBA-Geigy in the UK as Medical Advisor, then European Medical Director for Syntex, and joined Merck, first in the international division after graduating in business studies from Columbia University, New York City, then as Assistant Editor of The Merck Manual. He teaches pharmaceutical medicine, bioethics and medical and scientific writing at Temple University’s School of Pharmacy. He is a founder member and former trustee of the Academy of Pharmaceutical Physicians and Investigators (formerly the American Academy of Pharma- ceutical Physicians). Dr. Fletcher resides in Ohio. ANTHONY (‘Tony’) W. FOX, BSc, MBBS, FFPM, FRCP, MD(Lond), DipPharmMedRCP, CBiol, FIBiol, is President of EBD Group, a consultancy with offices in San Diego and Munich. From the Royal London Hospital, after general clinical training, he was Rotary International Fellow at Emory University (Atlanta) and CIBA-Geigy Fellow at Harvard. Industrial positions at Procter & Gamble and (then) Glaxo Inc. came next. He has also been a clinical and regulatory Vice President within a small pharmaceutical company. Among many societies, Tony was a Charter Member, Trustee, and Education VP of the American Academy of Pharmaceutical Physicians, and is a liveryman guardant of the Worshipful Society of Apothecaries of London. He is an Adjunct (i.e. honorary) Associate Clinical Professor in the Skaggs School of Pharmacy and
  11. 11. xiv ABOUT THE EDITORS Pharmaceutical Sciences, at the University of California, San Diego. His publications span several areas of pharmaceutical medicine, for example, regulation, pharmacology, clinical trials, pharmacovigilance, analgesics, migraine, genotoxicology, and metabolism, and he is named as inventor on several patents. He is on the editorial boards of several journals, and serves in a more senior capacity for two of them. Tony is proud to be an Essex man, researches the history of that County, and has been elected as a fellow of the Royal Geographical and the Royal Numismatic Societies. PETER D. STONIER, BA, BSc, PhD, MBChB, MRCPsych, FRCP, FRCPE, FFPM has 29 years experience in pharmaceutical medicine. He is a graduate of Manchester Medical School, qualifying in 1974, following a BSc degree in physiology (University of Birmingham) and a PhD in protein chemistry (University of Sheffield). He is a pharmaceutical physician and was Medical Adviser with the UK Hoechst Group of companies from 1977, serving as Medical Director and Board Director until 2000. Currently, he is Director of Education and Training of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians of the UK. He is Medical Director of Amdipharm Plc, and of Medical Resource Provider Axess Ltd. Formerly, he was President of the International Federation of Associations of Pharmaceutical Physicians (IFAPP) and Chairman of the British Association of Pharmaceutical Physicians. He is a past- President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK. He is Visiting Professor in pharmaceutical medicine at the University of Surrey, which under his direction introduced the first MSc degree in Pharmaceutical Medicine in 1993, which is now part of the Postgraduate Medical School of the University. His publications include edited works in human psychopharmacology, pharmaceutical medicine, clinical research, medical marketing, and careers in the pharmaceutical industry. He is a member of the Association of Pharmaceutical Physicans and Investigators (APPI). Professor Stonier has been elected a Fellow of the Royal Society for the encouragement of Arts, Manufactures and Commerce.
  12. 12. Contributors Anbar, Dan ClinPro Inc., 1661 Route 22 West, Round Brook, NJ 08805, USA. Email: Ball, Graham Good Clinical Research Practices Consultants, Lakehurst, Ontario, Canada, and Oxford, UK. Barrett, Jane 2 Falcon Way, Wokingham, Berkshire RG41 3HD, UK. Email: Belsey, Jonathan JB Medical, The Old Brickworks, Chapel Lane, Little Cornard, Sudbury, Suffolk CO10 0PB, UK. Email: Bohaychuk, Wendy Good Clinical Research Practices Consultants, Lakehurst, Ontario, Canada, and Oxford, UK. Boyer, J. Gregory Accreditation Council for Pharmacy Education, Chicago, IL, USA Castle, Win M. Formerly of GlaxoSmithKline, Philadelphia, PA, USA. Email: Chaponis, Robert J. US Medical Operations, Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA. Email: Choi, Han W. Oracle Investment Management Inc., 200 Greenwich Ave 3rd Fl., Greenwich, CT 06830, USA. Email: Cobb, Ronald R. RiverWood BioConsulting Inc., 8909 SW 75th Street, Gainesville, FL 32608, USA. Croft, Sara Shook, Hardy and Bacon International LLP, London, UK and Shook, Hardy and Bacon LLP, Kansas City, MO, USA Curry, Stephen H. Department of Pharmacology and Physiology, University of Rochester, Rochester, NY 14627, USA. Email: Dabbous, Omar H. Health Economics & Clinical Outcomes Research, Medical Affairs, Centocor Inc., 800 Ridgeview Drive, Horsham, PA 19044, USA. DeCory, Heleen H. UCB, 755 Jefferson Road, Rochester, NY, USA Dreskin, Howard J. 7809 Via Optuntia, Carlsbad, CA 92009, USA. Formerly of GlaxoSmithKline, Philadelphia, PA, USA. Email:
  13. 13. xvi CONTRIBUTORS Drucker, R. Technomark Consulting Services Ltd, King House, 11 Westbourne Grove, London W2 4UA, UK. Email: Dziewanowska, Zofia Ligand Pharmaceuticals Inc., 10275 Science Center Drive, San Diego, CA 92121, USA. Email: Edwards, Lionel D. Novartis Pharmaceuticals Corporation, US CD&MA, Building 501/Room 216, One Health Plaza, East Hanover, NJ 07936-1080, USA. Email: Fletcher, Andrew J. Temple University School of Pharmacy, PHARM-QA/RA, 3307 North Broad Street, Philadelphia, PA 19140, USA. Email: Fox, Anthony W. EBD Group Inc., 2032 Corte del Nogal #120, Carlsbad, CA 92011, USA and Neuhauser Straße 3, Munich, D-80331, Germany. Email:; ¨ Freidank-Muschenborn, Edda International Regulatory Affairs, Engelhard Arzneimittel GmbH, Herzbergstrasse 3, 61138 Niederdorfelden, Germany. Email: Gabrielsson, Johan AstraZeneca R&D, Wilmington, DE, USA Geba, Gregory P. Novartis Pharmaceuticals Corporation, One Health Plaza, Building 701, East Hanover, NJ 07936-1080, USA. Email: Griffin, John P. John Griffin Associates Ltd, Quartermans, Digswell Lane, Digswell, Welwyn, Hertfordshire AL7 1SP, UK. Email: Hammad, Gamal 24 Cassiobury Park Avenue, Watford, Hertfordshire WD18 7LB, UK. Email: Hanson-Divers, Christine Cary, NC, USA Hattemer-Apostel, Rita Verdandi AG, Wieslergasse 2, 8049 Zurich, Switzerland. Email: Hoxie, Thomas Hoxie & Tso LLP, 374 Millburn Avenue, Suite 300E, Millburn, NJ 07041, USA Hughes, R. Graham Technomark Consulting Services Ltd, King House, 11 Westbourne Grove, London W2 4UA, UK. Email: Husson, J.M. Paris, France Johnson-Pratt, Lisa R. Wynnewood, PA, USA. Email: Kennedy, William Consultant, Delaware, USA; formerly V.P. Regulation Affairs. Email: ¨ Konig, Anja International Regulatory Affairs, Engelhard Arzneimittel GmbH, Herzbergstrasse 3, 61138 Niederdorfelden, Germany. Email:
  14. 14. CONTRIBUTORS xvii ´ ´ Labbe, Etienne UCB S.A., Allee de la Recherche, 60, 1070 Brussels, Belgium. Email: Lee, T.Y. ACER/EXCEL Inc., USA. Lopez, Gabriel 6 Pleasantville Road, New Vernon, NJ 07976, USA. Email: Marler, Matthew Department of Psychiatry, University of California, San Diego, CA, USA McCarthy, Dennis AstraZeneca R&D, Wilmington, DE, USA Mann, Ronald D. 42 Hazleton Way, Waterlooville, Hampshire PO8 9BT, UK. Email: Marks, Peter Pfizer Inc., 50 Pequot Avenue, MS 6025-C4247, New London, CT 06320, USA. Email: ´ Metry, Jean-Michel AARDEX Ltd, Untermueli 6, Postfach 2026, 6302 Zug, Switzerland. Email: Minor, Michael ACER/EXCEL Inc., USA Miskin, Barry University of Florida, College of Medicine, PO Box 8068, Jupiter, FL 33468, USA. Email: Molony, Leslie J. RiverWood BioConsulting Inc., 8909 SW 75th Street, Gainesville, FL 32608, USA. Email: Naito, C. Teikyo University, Japan Osterhaus, Jane T. Wasatch Health Outcomes, Park City, UT and Carlsbad, CA, USA. Email: Packard, Linda Formerly American Academy of Pharmaceutical Physicians, Research Triangle Park, NC, USA Papaluca Amati, M. EMEA, London, UK Pratt, Timothy Shook, Hardy and Bacon International LLP, London, UK and Shook, Hardy and Bacon LLP, Kansas City, MO, USA Rahman, Mirza I. Health Economics & Clinical Outcomes Research, Medical Affairs, Centocor Inc., 800 Ridgeview Drive, Horsham, PA 19044, USA. Email: Reno, Frederick Merritt Island, FL, USA. Email: Shapiro, David A. Integrated Quality Resources, PO Box 8530, Rancho Santa Fe, CA 92067, USA. Email: Spilker, Bert Bert Spilker Associates, 8004 Overhill Road, Bethesda, MD 20814-1145, USA. Email: Starkey, Paul Formerly SmithKline Beecham Healthcare, Parsippany, NJ, USA. Email: Stonier, Peter D. 5 Branstone Road, Kew, Richmond, Surrey TW9 3LB, UK. Email:
  15. 15. xviii CONTRIBUTORS Tabusso, Giuliana Via Melchiorre Gioia 47, 20124 Milan, Italy. Email: Tilson, Hugh H. Office of the Dean, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7400, USA. Email: Townsend, Raymond J. Elan Pharmaceuticals, 7475 Lusk Boulevard, San Diego, CA 9212, USA. Email: Turner, Nadia Astra-Zeneca Pharmaceuticals, Macclesfield, UK van Troostenburg de Bruyn, Anne-Ruth Takeda Global R&D Centre (Europe), Arundel Great Court, 2 Arundel Street, London WC2R 3DA, UK. Email: Vogel, John R. John R. Vogel Associates Inc., 328 Pualoa Nani Place, Kihei, HI 96753, USA. Email:; Walker, S. Centre of Medicine Research, Carlshalton, UK Wells, Marilyn J. Hampton University, Hampton, VA 23668, USA Williams, R. US Pharmacopia, Rockville, MD, USA Yasurhara, H. Teikyo University, Japan Yeon, Howard B. Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Email: Young, Michael D. MDY-Associates, Philadelphia, PA, USA. Email:
  16. 16. SECTION I Overview of Pharmaceutical Medicine
  17. 17. 1 ThePharmaceuticalPractitioners of Practice and Medicine Anthony W. Fox Pharmaceutical medicine is unquestionably a strate efficacy, tolerability and purity in drug young medical specialty. The first university chair products (and their equivalents in diagnostics and in pharmaceutical medicine is less than 10 years old, devices), pharmaceutical medicine has become and there are no great buildings or institutions evidence based; it is interesting to note that the dedicated to it, unlike venerable medical specialties more venerable medical specialties are now imitat- such as chest medicine, neurology, physiology, ing the supposed ‘new kids on the block’ with the pharmacology and so on. Possibly because of its recent emphasis on evidence-based approaches to youth, this is a specialty that can be misunderstood the patient. by those outside it. Even among practitioners of It is therefore not surprising that the diverse and pharmaceutical medicine, there can be surprise overlapping discipline of pharmaceutical medicine when they consider their own diversity. is populated by practitioners with varied educa- Nonetheless, elements of what we recognize tional backgrounds. There can be no doubt that today as the practice of pharmaceutical medicine clinical experience is always a good prelude to a have existed for a long time. Withering’s identifi- career in pharmaceutical medicine. But dental sur- cation of Digitalis purpurea as a treatment for what geons, medical practitioners, nurses, pharmacists, was then called ‘dropsy’ and the clinical trial of physiotherapists, psychologists and many other citrus fruit conducted by Lind are examples of drug members of the allied health professions have all discovery and investigation. Sequential clinical found satisfying careers in this specialty. trial designs have been borrowed from as far Few medical specialties involve working in a-field as the discipline of engineering and date teams with as large a number of other professions from the mid-twentieth century. The techniques as of pharmaceutical medicine. For example, gen- shared with the fields of epidemiology and public eral practitioners regularly work with nurses, health health are obvious and also well established. Every visitors, administrators, hospital colleagues and prescription written in ordinary clinical practice is social workers; radiologists might add radiogra- a clinical trial of some sort, where n ¼ 1, because phers and physicists to this list and delete the health human beings are anisogenetic; this even applies to visitors and social workers. But, by way of compar- identical twins as they age or are exposed to dif- ison, the following list of nouns, all of which have ferent environments. Ever since the need to demon- their own professions, comprise pharmaceutical Principles and Practice of Pharmaceutical Medicine, 2nd Edition Edited by L. D. Edwards, A. J. Fletcher, A. W. Fox and P. D. Stonier # 2007 John Wiley & Sons, Ltd ISBN: 978